Literature DB >> 19273294

Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology.

Persoulla Nicolaou1, Evangelia G Kranias.   

Abstract

Type 1 protein phosphatase (PP1) is a critical regulator of several cellular processes. In the heart, it mediates restoration of contractility to basal levels by dephosphorylating key phospho-proteins, after beta-adrenergic stimulation. PP1 is a holoenzyme consisting of its catalytic and regulatory subunits, which anchor the catalytic subunit to desired subcellular locations, define substrate specificity and modulate catalytic activity. At the level of the cardiac sarcoplasmic reticulum (SR), PP1 is regulated by Inhibitor-1 (I-1) and Inhibitor-2 (I-2), which modulate its activity, and the striated muscle-specific glycogen-targeting subunit, GM/RGL, which targets it to the SR vicinity. PP1 regulation is highly important in maintaining cardiac function under physiological conditions. In fact, aberrant Ca handling and depressed contractility in heart failure have been, at least partly, attributed to increases in PP1 activity, mediated by impaired regulation via its inhibitors. Importantly, increases in the level and activity of I-1 and I-2 in animal models have been successful in ameliorating dysfunction and remodeling in heart failure, suggesting that PP1 inhibition may be a plausible therapeutic strategy in heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273294      PMCID: PMC2663387          DOI: 10.2741/3472

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  103 in total

1.  Phosphorylation of the skeletal muscle glycogen-targetting subunit of protein phosphatase 1 in response to adrenaline in vivo.

Authors:  K S Walker; P W Watt; P Cohen
Journal:  FEBS Lett       Date:  2000-01-21       Impact factor: 4.124

2.  Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1.

Authors:  J Goldberg; H B Huang; Y G Kwon; P Greengard; A C Nairn; J Kuriyan
Journal:  Nature       Date:  1995-08-31       Impact factor: 49.962

3.  Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats.

Authors:  Ramesh C Gupta; Sudhish Mishra; Xiao-Ping Yang; Hani N Sabbah
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

4.  Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.

Authors:  K X Huang; H K Paudel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 5.  Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions.

Authors:  Alicia Mattiazzi; Cecilia Mundiña-Weilenmann; Chu Guoxiang; Leticia Vittone; Evangelia Kranias
Journal:  Cardiovasc Res       Date:  2005-10-13       Impact factor: 10.787

6.  Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy.

Authors:  M Meyer; W Schillinger; B Pieske; C Holubarsch; C Heilmann; H Posival; G Kuwajima; K Mikoshiba; H Just; G Hasenfuss
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

7.  Fluorescence studies on the interaction of inhibitor 2 and okadaic acid with the catalytic subunit of type 1 phosphoprotein phosphatases.

Authors:  W D Picking; W Kudlicki; G Kramer; B Hardesty; J R Vandenheede; W Merlevede; I K Park; A DePaoli-Roach
Journal:  Biochemistry       Date:  1991-10-22       Impact factor: 3.162

8.  PKC-alpha regulates cardiac contractility and propensity toward heart failure.

Authors:  Julian C Braz; Kimberly Gregory; Anand Pathak; Wen Zhao; Bogachan Sahin; Raisa Klevitsky; Thomas F Kimball; John N Lorenz; Angus C Nairn; Stephen B Liggett; Ilona Bodi; Su Wang; Arnold Schwartz; Edward G Lakatta; Anna A DePaoli-Roach; Jeffrey Robbins; Timothy E Hewett; James A Bibb; Margaret V Westfall; Evangelia G Kranias; Jeffery D Molkentin
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

9.  Digenic inheritance of severe insulin resistance in a human pedigree.

Authors:  David B Savage; Maura Agostini; Inês Barroso; Mark Gurnell; Jian'an Luan; Aline Meirhaeghe; Anne-Helen Harding; Gudrun Ihrke; Odelia Rajanayagam; Maria A Soos; Stella George; Dirk Berger; E Louise Thomas; Jimmy D Bell; Karim Meeran; Richard J Ross; Antonio Vidal-Puig; Nicholas J Wareham; Stephen O'Rahilly; V Krishna K Chatterjee; Alan J Schafer
Journal:  Nat Genet       Date:  2002-07-15       Impact factor: 38.330

10.  A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice.

Authors:  David B Savage; Lanmin Zhai; Balasubramanian Ravikumar; Cheol Soo Choi; Johanna E Snaar; Amanda C McGuire; Sung-Eun Wou; Gemma Medina-Gomez; Sheene Kim; Cheryl B Bock; Dyann M Segvich; Bhavana Solanky; Dinesh Deelchand; Antonio Vidal-Puig; Nicholas J Wareham; Gerald I Shulman; Fredrik Karpe; Roy Taylor; Bartholomew A Pederson; Peter J Roach; Stephen O'Rahilly; Anna A DePaoli-Roach
Journal:  PLoS Med       Date:  2008-01-29       Impact factor: 11.069

View more
  16 in total

1.  Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging.

Authors:  Stela Florea; Ahmad Anjak; Wen-Feng Cai; Jiang Qian; Elizabeth Vafiadaki; Sarah Figueria; Kobra Haghighi; Jack Rubinstein; John Lorenz; Evangelia G Kranias
Journal:  Basic Res Cardiol       Date:  2012-07-10       Impact factor: 17.165

Review 2.  Mechanisms of altered Ca²⁺ handling in heart failure.

Authors:  Min Luo; Mark E Anderson
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

3.  Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart.

Authors:  Sean T DeGrande; Sean C Little; Derek J Nixon; Patrick Wright; Jedidiah Snyder; Wen Dun; Nathaniel Murphy; Ahmet Kilic; Robert Higgins; Philip F Binkley; Penelope A Boyden; Cynthia A Carnes; Mark E Anderson; Thomas J Hund; Peter J Mohler
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

4.  Ca2+ cycling and new therapeutic approaches for heart failure.

Authors:  Anne-Marie Lompré; Roger J Hajjar; Sian E Harding; Evangelia G Kranias; Martin J Lohse; Andrew R Marks
Journal:  Circulation       Date:  2010-02-01       Impact factor: 29.690

5.  Protein Phosphatase-1 regulates Rift Valley fever virus replication.

Authors:  Alan Baer; Nazly Shafagati; Ashwini Benedict; Tatiana Ammosova; Andrey Ivanov; Ramin M Hakami; Kaori Terasaki; Shinji Makino; Sergei Nekhai; Kylene Kehn-Hall
Journal:  Antiviral Res       Date:  2016-01-20       Impact factor: 5.970

6.  Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+ -ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells.

Authors:  Larissa Lipskaia; Regis Bobe; Jiqiu Chen; Irene C Turnbull; Jose J Lopez; Elise Merlet; Dongtaq Jeong; Ioannis Karakikes; Alexandra S Ross; Lifan Liang; Nathalie Mougenot; Fabrice Atassi; Anne-Marie Lompré; Sima T Tarzami; Jason C Kovacic; Evangelia Kranias; Roger J Hajjar; Lahouaria Hadri
Journal:  Circulation       Date:  2013-11-18       Impact factor: 29.690

Review 7.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science.

Authors:  Ajay M Shah; Douglas L Mann
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

Review 8.  Regulation of Cardiac PKA Signaling by cAMP and Oxidants.

Authors:  Friederike Cuello; Friedrich W Herberg; Konstantina Stathopoulou; Philipp Henning; Simon Diering
Journal:  Antioxidants (Basel)       Date:  2021-04-24

9.  An Ultra-High-Throughput Screen for Catalytic Inhibitors of Serine/Threonine Protein Phosphatases Types 1 and 5 (PP1C and PP5C).

Authors:  Mark Swingle; Claude-Henry Volmar; S Adrian Saldanha; Peter Chase; Christina Eberhart; Edward A Salter; Brandon D'Arcy; Chad E Schroeder; Jennifer E Golden; Andrzej Wierzbicki; Peter Hodder; Richard E Honkanen
Journal:  SLAS Discov       Date:  2016-09-27       Impact factor: 3.341

10.  Broad-scale phosphoprotein profiling of beta adrenergic receptor (β-AR) signaling reveals novel phosphorylation and dephosphorylation events.

Authors:  Andrzej J Chruscinski; Harvir Singh; Steven M Chan; Paul J Utz
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.